Novocure Ltd (NVCR NASDAQ) stock market data APIs
$12.2391
0.35(2.9%)
as of September 12, 2025
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
12.2391
Open
12.5935
High
12.8364
Low
12.2391
52 wk Range
10.87-34.13
Market Cap
1 358 M
Shares Outstanding
112 M
Revenue
630 M
EPS
-0.36
Beta
0.583
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novocure Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 630 M
- EBITDA: -158 863 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-24
- EPS/Forecast: -0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
Insider Spends US$997k Buying More Shares In NovoCure
NovoCure Limited (NASDAQ:NVCR) shareholders (or potential shareholders) will be happy to see that the CEO & Director, Ashley Cordova, recently bought a whopping US$997k worth of stock, at a price of U...
NovoCure (NVCR) Is Up 5.4% After Spain Reimburses TTFields Therapy—Has The Bull Case Changed?
Spain's Ministry of Health recently made NovoCure's Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System for adults with newly diagnosed glioblastoma, expandin...
Novocure Announces Upcoming Investor Events
BAAR, Switzerland, August 28, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference...
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
Eligible patients can receive TTFields therapy through the Spanish National Health System BAAR, Switzerland, August 25, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Spain’s M...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
